Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence

计划入组 16 人 · 首次发布于 2025 年 8 月 24 日

Seven Year Update of Macular Degeneration Patients

计划入组 65 人 · 首次发布于 2010 年 12 月 9 日

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

计划入组 5,700 人 · 首次发布于 2026 年 4 月 8 日

2-aminoethanethiol dioxygenase inhibitors (Horizon Pharma)

Receptor-associated protein therapeutics (Horizon Therapeutics plc)

NUMARZU-001

Horizon Health Network

Canada

Horizon Therapeutics Ireland Designated Activity Company

Belgium

Horizon Pharmaceuticals, Inc.

United States

MMRF's Horizon Trial Program Enrolls First Patient to Optimize Myeloma Treatment

Amgen's Rocatinlimab Shows Promise in Eczema Trial, Myasthenia Gravis Treatment Also Succeeds

Novartis Extends Timeline for Pelacarsen Phase 3 Cardiovascular Trial to 2026